معرفی
Dr. Erik Lipsic is an interventional cardiologist at the Faculty of Medical Sciences, University of Groningen, working within the Vascular Medicine department at the University Medical Center Groningen (UMCG). He serves as a member of the PCI Registration Committee of the Netherlands Heart Registration and has significant research involvement in cardiovascular interventions. His clinical expertise focuses on coronary artery disease, myocardial infarction, and interventional cardiology techniques.
Dr. Lipsic's research interests span multiple critical areas of cardiovascular medicine. His primary focus includes ST-elevation myocardial infarction (STEMI), percutaneous coronary intervention optimization, and management of cardiogenic shock. He investigates high-risk plaque characteristics in non-culprit lesions, left atrial strain as a prognostic marker, and heart failure with preserved ejection fraction in valvular heart disease. His work bridges clinical practice with cutting-edge cardiac imaging and biomarker research to improve patient outcomes in acute coronary syndromes.
Analysis of Dr. Lipsic's recent publications (2024-2025) reveals a strong emphasis on real-world registry data from the Netherlands Heart Registration. His research demonstrates expertise in mechanical circulatory support applications for cardiogenic shock, stent optimization techniques during PCI, and the relationship between structural heart disease and functional outcomes. A notable trend is his investigation of imaging biomarkers (particularly left atrial strain) as predictors of long-term heart failure outcomes following myocardial infarction.
Dr. Lipsic serves as Principal Investigator for the 'Optimization of patient selection for percutaneous valve interventions' study sponsored by Abbott and as Co-Principal Investigator for the GIPS-IV study funded by ZonMW. He has received speaking fees from Amgen and the Netherlands Vascular Forum, indicating recognition of his expertise in the field. His research has generated significant academic impact, with multiple publications in high-impact cardiology journals.
Dr. Lipsic actively supervises research, with records indicating 10 supervised students. His collaborative network extends across numerous European institutions, particularly through the Netherlands Heart Registration PCI committee. His research is supported by both industry funding (Abbott) and national research councils (ZonMW), reflecting the translational nature of his work from basic mechanisms to clinical applications. He is involved in multiple clinical trials investigating novel approaches to patient selection for percutaneous valve interventions and optimization of coronary interventions.
As a member of the Vascular Medicine department at UMCG, Dr. Lipsic contributes to one of the Netherlands' leading cardiovascular research and treatment centers. His work with the Netherlands Heart Registration places him at the forefront of national efforts to improve quality of care in interventional cardiology. His research team focuses on translating imaging findings and biomarker research into clinical practice to improve risk stratification and treatment selection for patients with acute coronary syndromes and structural heart disease.
